LTPA2020512I1 - Antinksčių hormoną modifikuojančio agento panaudojimas - Google Patents

Antinksčių hormoną modifikuojančio agento panaudojimas

Info

Publication number
LTPA2020512I1
LTPA2020512I1 LTPA2020512C LTPA2020512C LTPA2020512I1 LT PA2020512 I1 LTPA2020512 I1 LT PA2020512I1 LT PA2020512 C LTPA2020512 C LT PA2020512C LT PA2020512 C LTPA2020512 C LT PA2020512C LT PA2020512 I1 LTPA2020512 I1 LT PA2020512I1
Authority
LT
Lithuania
Prior art keywords
modifying agent
adrenal hormone
hormone modifying
adrenal
agent
Prior art date
Application number
LTPA2020512C
Other languages
English (en)
Original Assignee
Recordati Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43735742&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LTPA2020512(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Recordati Ag filed Critical Recordati Ag
Publication of LTPA2020512I1 publication Critical patent/LTPA2020512I1/lt
Publication of LTC2523731I2 publication Critical patent/LTC2523731I2/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/645Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having two nitrogen atoms as the only ring hetero atoms
    • C07F9/6503Five-membered rings
    • C07F9/6506Five-membered rings having the nitrogen atoms in positions 1 and 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41881,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
LTPA2020512C 2010-01-14 2020-06-19 Antinksčių hormoną modifikuojančio agento panaudojimas LTC2523731I2 (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29498010P 2010-01-14 2010-01-14
PCT/US2011/021100 WO2011088188A1 (en) 2010-01-14 2011-01-13 Use of an adrenal hormone-modifying agent

Publications (2)

Publication Number Publication Date
LTPA2020512I1 true LTPA2020512I1 (lt) 2020-07-27
LTC2523731I2 LTC2523731I2 (lt) 2022-05-10

Family

ID=43735742

Family Applications (2)

Application Number Title Priority Date Filing Date
LTEP11702096.6T LT2523731T (lt) 2010-01-14 2011-01-13 Antinksčių hormoną modifikuojančio agento panaudojimas
LTPA2020512C LTC2523731I2 (lt) 2010-01-14 2020-06-19 Antinksčių hormoną modifikuojančio agento panaudojimas

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LTEP11702096.6T LT2523731T (lt) 2010-01-14 2011-01-13 Antinksčių hormoną modifikuojančio agento panaudojimas

Country Status (33)

Country Link
US (2) US8609862B2 (lt)
EP (2) EP3527208A1 (lt)
JP (4) JP5602250B2 (lt)
KR (1) KR101412206B1 (lt)
CN (2) CN105440038A (lt)
AU (1) AU2011205290C1 (lt)
BR (1) BR112012017458B1 (lt)
CA (1) CA2786443C (lt)
CL (1) CL2012001961A1 (lt)
CY (2) CY1121320T1 (lt)
DK (1) DK2523731T3 (lt)
ES (1) ES2707596T3 (lt)
HR (1) HRP20190064T1 (lt)
HU (2) HUE041967T2 (lt)
IL (1) IL220804A0 (lt)
LT (2) LT2523731T (lt)
LU (1) LUC00159I2 (lt)
MA (1) MA33904B1 (lt)
ME (1) ME03371B (lt)
MX (2) MX354022B (lt)
NL (1) NL301043I2 (lt)
NO (1) NO2020012I1 (lt)
NZ (1) NZ601077A (lt)
PL (1) PL2523731T3 (lt)
PT (1) PT2523731T (lt)
RS (1) RS58234B1 (lt)
RU (1) RU2598708C2 (lt)
SG (1) SG182393A1 (lt)
SI (1) SI2523731T1 (lt)
TN (1) TN2012000352A1 (lt)
TR (1) TR201900515T4 (lt)
WO (1) WO2011088188A1 (lt)
ZA (1) ZA201205058B (lt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2786443C (en) * 2010-01-14 2018-12-11 Novartis Ag Use of an adrenal hormone-modifying agent
US9078886B2 (en) 2010-06-16 2015-07-14 Embera Neurotherapeutics, Inc. Compositions for the treatment of addiction, psychiatric disorders, and neurodegenerative disease
TWI518073B (zh) 2011-06-14 2016-01-21 美國禮來大藥廠 醛固酮合成酶抑制劑
EP2757884B1 (en) 2011-09-22 2022-07-27 Merck Sharp & Dohme LLC Pyrazolopyridyl compounds as aldosterone synthase inhibitors
WO2013043520A1 (en) 2011-09-22 2013-03-28 Merck Sharp & Dohme Corp. Triazolopyridyl compounds as aldosterone synthase inhibitors
US20140235667A1 (en) 2011-09-22 2014-08-21 Merck Sharp & Dohme Corp. Imidazopyridyl compounds as aldosterone synthase inhibitors
UA114803C2 (uk) * 2012-01-17 2017-08-10 Новартіс Аг ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ
CA2869442C (en) * 2012-04-12 2020-09-08 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors
EP2903615B1 (en) 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
JP2015093832A (ja) * 2013-11-08 2015-05-18 日本メジフィジックス株式会社 放射性ハロゲン標識化合物又はその塩、これを含む医薬
EA033685B1 (ru) * 2014-07-07 2019-11-15 Novartis Ag Фармацевтические лекарственные формы
WO2016048984A1 (en) * 2014-09-25 2016-03-31 Cortendo Ab (Publ) Methods and compositions for the treatment of cushing's syndrome using 2s, 4r ketoconazole
PL3250555T3 (pl) * 2015-01-29 2021-08-02 Recordati Ag Sposób wytwarzania skondensowanych pochodnych imidazolu
US20160287565A1 (en) 2015-04-06 2016-10-06 Millendo Therapeutics, Inc. Combination therapy for treating disorders associated with excess cortisol production
RU2018101864A (ru) * 2015-06-22 2019-07-22 Эмбера Ньюротерапьютикс, Инк. Композиции и способы для лечения нарушений, связанных с употреблением веществ, зависимости и психических расстройств
BR112019018700A2 (pt) 2017-03-10 2020-04-07 Embera Neurotherapeutics Inc composições farmacêuticas e seus usos

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4889861A (en) * 1982-12-21 1989-12-26 Ciba-Geigy Corp. Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
US4814333A (en) 1987-07-28 1989-03-21 The Trustees Of Dartmouth College Method for treatment of hypercortisolemic, depressed patients
US5503843A (en) 1994-04-22 1996-04-02 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
US5658881A (en) 1994-10-14 1997-08-19 Twk, Inc. Method for topical inhibition of the metabolic activity of cytochrome P450
DE19814087A1 (de) * 1998-03-30 1999-10-14 Lohmann Therapie Syst Lts Feuchtigkeitsaktivierbares therapeutisches System
US7417038B1 (en) 1998-10-15 2008-08-26 Imperial Innovations Limited Methods of treating cachexia
EP1392676B1 (en) 2001-02-16 2006-12-13 Aventis Pharmaceuticals Inc. Heterocyclic urea derivatives and their use as dopamine d3 receptor ligands
TWI263640B (en) 2001-12-19 2006-10-11 Bristol Myers Squibb Co Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
GB0212412D0 (en) * 2002-05-29 2002-07-10 Novartis Ag Combination of organic compounds
JP5138875B2 (ja) 2005-07-19 2013-02-06 株式会社デンソー センサ装置
GT200600381A (es) * 2005-08-25 2007-03-28 Compuestos organicos
AR056888A1 (es) 2005-12-09 2007-10-31 Speedel Experimenta Ag Derivados de heterociclil imidazol
CA2645678A1 (en) 2006-03-16 2007-09-20 Yeda Research And Development Co. Ltd. Method and composition for protecting neuronal tissue from damage induced by elevated glutamate levels
MX2008015008A (es) * 2006-05-26 2008-12-05 Novartis Ag INHIBIDORES DE SINTASA DE ALDOSTERONA Y/O DE 11ß-HIDROXILASA.
EP1886695A1 (en) 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
US20090264420A1 (en) * 2006-08-25 2009-10-22 Gary Michael Ksander Organic compounds
KR20090090395A (ko) * 2006-12-18 2009-08-25 노파르티스 아게 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도
EP2095819A1 (en) 2008-02-28 2009-09-02 Maastricht University N-benzyl imidazole derivatives and their use as aldosterone synthase inhibitors
AR072297A1 (es) 2008-06-27 2010-08-18 Novartis Ag Derivados de indol-2-il-piridin-3-ilo, composicion farmaceutica que los comprende y su uso en medicamentos para el tratamiento de enfermedades mediadas por la sintasa aldosterona.
CA2786443C (en) * 2010-01-14 2018-12-11 Novartis Ag Use of an adrenal hormone-modifying agent
UA114803C2 (uk) * 2012-01-17 2017-08-10 Новартіс Аг ФОРМИ І СОЛІ ДИГІДРОПІРОЛ[1,2-c]ІМІДАЗОЛІЛЬНОГО ІНГІБІТОРА АЛЬДОСТЕРОНСИНТАЗИ АБО АРОМАТАЗИ
CA2869442C (en) * 2012-04-12 2020-09-08 Novartis Ag Combination of somatostatin-analogs with 11beta-hydroxylase inhibitors

Also Published As

Publication number Publication date
PT2523731T (pt) 2019-01-21
JP2017002063A (ja) 2017-01-05
LUC00159I2 (lt) 2021-07-06
TR201900515T4 (tr) 2019-02-21
PL2523731T3 (pl) 2019-04-30
RS58234B1 (sr) 2019-03-29
JP5602250B2 (ja) 2014-10-08
US20120295888A1 (en) 2012-11-22
DK2523731T3 (en) 2019-02-04
CL2012001961A1 (es) 2013-03-22
AU2011205290C1 (en) 2014-11-06
MA33904B1 (fr) 2013-01-02
CA2786443A1 (en) 2011-07-21
IL220804A0 (en) 2012-08-30
CN102711916B (zh) 2015-09-02
ES2707596T3 (es) 2019-04-04
JP2013517280A (ja) 2013-05-16
CY2020018I1 (el) 2020-11-25
JP6425688B2 (ja) 2018-11-21
LTC2523731I2 (lt) 2022-05-10
JP2015013859A (ja) 2015-01-22
JP6181610B2 (ja) 2017-08-16
MX354022B (es) 2018-02-08
NL301043I1 (nl) 2020-06-17
BR112012017458B1 (pt) 2020-10-20
ZA201205058B (en) 2014-04-30
US8609862B2 (en) 2013-12-17
CN105440038A (zh) 2016-03-30
AU2011205290B2 (en) 2014-06-26
KR20120116482A (ko) 2012-10-22
KR101412206B1 (ko) 2014-06-25
CN102711916A (zh) 2012-10-03
JP2018150326A (ja) 2018-09-27
RU2598708C2 (ru) 2016-09-27
HRP20190064T1 (hr) 2019-03-08
NO2020012I1 (no) 2020-06-09
EP2523731A1 (en) 2012-11-21
WO2011088188A1 (en) 2011-07-21
BR112012017458A2 (pt) 2017-12-19
HUS000508I2 (hu) 2021-03-29
NL301043I2 (nl) 2020-07-06
HUS2000018I1 (hu) 2020-07-28
EP3527208A1 (en) 2019-08-21
LT2523731T (lt) 2019-02-11
RU2012134510A (ru) 2014-02-20
SI2523731T1 (sl) 2019-02-28
EP2523731B1 (en) 2018-10-24
US9434754B2 (en) 2016-09-06
NZ601077A (en) 2014-07-25
CY2020018I2 (el) 2020-11-25
HUE041967T2 (hu) 2019-06-28
CY1121320T1 (el) 2020-05-29
CA2786443C (en) 2018-12-11
ME03371B (me) 2020-01-20
LUC00159I1 (lt) 2020-06-16
MX2012008212A (es) 2012-08-03
TN2012000352A1 (en) 2014-01-30
SG182393A1 (en) 2012-08-30
US20140171392A1 (en) 2014-06-19
AU2011205290A1 (en) 2012-08-02

Similar Documents

Publication Publication Date Title
LTPA2020512I1 (lt) Antinksčių hormoną modifikuojančio agento panaudojimas
SMT201500291B (it) Nuovi agenti antimalarici
DK2542600T3 (da) Vandige polyurethandispersioner
DK2525798T3 (da) Anæstetisk formulering
SMT201600219B (it) Ormone follicolo-stimolante ricombinante umano migliorato
BR112013009711A2 (pt) agente reticulante
FI9160U1 (fi) Pinnoituslaite
BR112012021749A2 (pt) processos e compostos
DK2455305T3 (da) Silo
DK2642980T3 (da) Pædiatrisk formulering
DK2598175T3 (da) Radiofarmaceutiske sammensætninger
ITGE20110047A1 (it) Miscelatore
BR112013014710A2 (pt) entrega de compostos funcionais
DE112011102778A5 (de) Magnetovariationales Verfahren
ES1071715Y (es) Aposito
PL2363354T3 (pl) Dozownik substancji czynnej
ITGE20110048A1 (it) Miscelatore
FI20105285A0 (fi) Sekoitin
UA21042S (uk) Комплект бланків
GB201009342D0 (en) Use of steroid compounds
TH119706B (th) ของผสมยาง
ES1072569Y (es) Jeringa mezcladora
UA21287S (uk) Бетономішалка
FI20100324A0 (fi) Vastavoiman hyödyksikäyttö
DOS2010000287S (es) Ducha (parte de)